Atara Biotherapeutics Stock Price, News & Analysis (NASDAQ:ATRA)

$43.65 -1.15 (-2.57 %)
(As of 02/22/2018 06:00 AM ET)
Previous Close$44.80
Today's Range$42.90 - $45.30
52-Week Range$11.80 - $49.90
Volume642,000 shs
Average Volume1.22 million shs
Market Capitalization$1.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.71

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics logoAtara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATRA
CUSIPN/A
Phone650-278-8930

Debt

Debt-to-Equity RatioN/A
Current Ratio12.49%
Quick Ratio12.49%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$8.79 per share
Price / Book4.97

Profitability

Trailing EPS($3.47)
Net Income$-79,040,000.00
Net MarginsN/A
Return on Equity-44.82%
Return on Assets-41.82%

Miscellaneous

Employees96
Outstanding Shares37,600,000

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its earnings results on Thursday, November, 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.97) by $0.05. View Atara Biotherapeutics' Earnings History.

Where is Atara Biotherapeutics' stock going? Where will Atara Biotherapeutics' stock price be in 2018?

6 brokers have issued 1 year price targets for Atara Biotherapeutics' stock. Their forecasts range from $18.00 to $70.00. On average, they expect Atara Biotherapeutics' share price to reach $34.50 in the next twelve months. View Analyst Ratings for Atara Biotherapeutics.

What are Wall Street analysts saying about Atara Biotherapeutics stock?

Here are some recent quotes from research analysts about Atara Biotherapeutics stock:

  • 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (2/15/2018)
  • 2. Canaccord Genuity analysts commented, "We view ANI’s recent purchase of four tail branded assets from AstraZeneca positively and we think the transaction is consistent with prior value-creating moves at the company. From the transaction, ANI will gain four modest but highly profitable branded products with the opportunity to expand margins further through in-sourcing manufacturing for the basket. Additionally, ANI enhanced its BD flexibility through a new credit facility that gives the company ample capacity to pursue additional transactions. With a solid core business and significant optionality associated with the Cortrophin development asset, we view ANI as one of the best-positioned names in our emerging generics space." (12/29/2017)

Who are some of Atara Biotherapeutics' key competitors?

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the folowing people:

  • Isaac E. Ciechanover M.D., Chairman of the Board, President, Chief Executive Officer (Age 46)
  • John F. McGrath Jr., Chief Financial Officer, Executive Vice President (Age 52)
  • Joseph Newell, Executive Vice President, Chief Technical Operations Officer (Age 47)
  • Christopher M. Haqq M.D. Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer (Age 50)
  • Heather D. Turner, Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy (Age 43)
  • Mitchall G. Clark, Executive Vice President and Chief Regulatory and Quality Assurance Officer (Age 55)
  • Gad Soffer, Executive Vice President and Chief Strategy Officer (Age 39)
  • Kanya Rajangam M.D. Ph.D., Senior Vice President, Chief Medical Officer
  • Carol G. Gallagher Pharm.D., Lead Independent Director (Age 52)
  • Eric L. Dobmeier, Independent Director (Age 48)

Who owns Atara Biotherapeutics stock?

Atara Biotherapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (8.37%), Redmile Group LLC (7.49%), Bridger Management LLC (6.91%), CAMBER CAPITAL MANAGEMENT LLC (6.65%), CAMBER CAPITAL MANAGEMENT LLC (6.65%) and BlackRock Inc. (5.22%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Eric Dobmeier, Gad Soffer, Heather D Turner, Isaac E Ciechanover, John Mcgrath and Mitchall G Clark. View Institutional Ownership Trends for Atara Biotherapeutics.

Who sold Atara Biotherapeutics stock? Who is selling Atara Biotherapeutics stock?

Atara Biotherapeutics' stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Redmile Group LLC, BlackRock Inc., Wells Fargo & Company MN, Metropolitan Life Insurance Co. NY, Vident Investment Advisory LLC, Rhumbline Advisers and Eagle Asset Management Inc.. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Gad Soffer, Heather D Turner, Isaac E Ciechanover, John Mcgrath and Mitchall G Clark. View Insider Buying and Selling for Atara Biotherapeutics.

Who bought Atara Biotherapeutics stock? Who is buying Atara Biotherapeutics stock?

Atara Biotherapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Bridger Management LLC, Artal Group S.A., ArrowMark Colorado Holdings LLC, Nexthera Capital LP, Deutsche Bank AG, Pacific Heights Asset Management LLC and Hudson Bay Capital Management LP. View Insider Buying and Selling for Atara Biotherapeutics.

How do I buy Atara Biotherapeutics stock?

Shares of Atara Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of Atara Biotherapeutics stock can currently be purchased for approximately $43.65.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $1.68 billion. The biotechnology company earns $-79,040,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis. Atara Biotherapeutics employs 96 workers across the globe.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.


MarketBeat Community Rating for Atara Biotherapeutics (ATRA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Atara Biotherapeutics (NASDAQ:ATRA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.602.402.20
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $34.50$34.50$26.75$25.75
Price Target Upside: 28.65% downside25.45% upside100.37% upside65.59% upside

Atara Biotherapeutics (NASDAQ:ATRA) Consensus Price Target History

Price Target History for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018CitigroupDowngradeNeutral -> SellHighView Rating Details
1/26/2018CowenInitiated CoverageOutperformHighView Rating Details
1/19/2018Canaccord GenuityReiterated RatingBuy -> Positive$47.00 -> $70.00LowView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral -> Neutral$20.00N/AView Rating Details
10/5/2017Jefferies GroupReiterated RatingBuy$30.00N/AView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
7/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$40.00 -> $34.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Atara Biotherapeutics (NASDAQ:ATRA) Earnings History and Estimates Chart

Earnings by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ ATRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.97)($1.02)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.89)($0.94)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.77)($0.88)ViewN/AView Earnings Details
3/9/201712/31/2016($0.98)($0.63)ViewN/AView Earnings Details
11/4/2016Q3 2016($0.79)($0.88)ViewN/AView Earnings Details
8/8/2016Q2($0.61)($0.66)ViewN/AView Earnings Details
5/5/2016Q1($0.55)($0.58)ViewN/AView Earnings Details
3/3/2016Q4 2015($0.48)($0.75)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.53)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.42)($0.43)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.36)($0.42)ViewN/AView Earnings Details
2/26/2015Q4 2014($0.35)($0.67)ViewN/AView Earnings Details
11/12/2014Q314($4.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Atara Biotherapeutics (NASDAQ:ATRA) Earnings Estimates

2018 EPS Consensus Estimate: ($3.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.89)($0.89)($0.89)
Q2 20181($0.88)($0.88)($0.88)
Q3 20181($0.90)($0.90)($0.90)
Q4 20181($0.92)($0.92)($0.92)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Atara Biotherapeutics (NASDAQ:ATRA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Atara Biotherapeutics (NASDAQ ATRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.20%
Institutional Ownership Percentage: 74.29%
Insider Trades by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)
Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ ATRA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Carol Giltner GallagherDirectorSell1,183$46.50$55,009.50111,286View SEC Filing  
2/16/2018Isaac E CiechanoverCEOSell20,000$46.92$938,400.00812,613View SEC Filing  
2/16/2018John McgrathCFOSell13,000$47.07$611,910.0099,056View SEC Filing  
2/14/2018Isaac E CiechanoverCEOSell20,000$46.80$936,000.00808,675View SEC Filing  
2/9/2018Heather D TurnerEVPSell12,214$38.01$464,254.1477,112View SEC Filing  
2/9/2018Isaac E CiechanoverCEOSell8,800$37.44$329,472.00808,675View SEC Filing  
1/26/2018Isaac E CiechanoverCEOSell19,300$35.26$680,518.00743,675View SEC Filing  
1/24/2018Isaac E CiechanoverCEOSell48,500$34.58$1,677,130.00348,978View SEC Filing  
1/22/2018Isaac E CiechanoverCEOSell10,000$33.07$330,700.00348,978View SEC Filing  
1/16/2018Isaac E CiechanoverCEOSell600$30.38$18,228.00743,675View SEC Filing  
1/12/2018Isaac E CiechanoverCEOSell28,700$21.39$613,893.00743,675View SEC Filing  
1/12/2018John McgrathCFOSell37,000$24.35$900,950.0093,154View SEC Filing  
1/10/2018Isaac E CiechanoverCEOSell8,600$19.99$171,914.00743,675View SEC Filing  
12/29/2017Isaac E CiechanoverCEOSell22,200$18.29$406,038.00View SEC Filing  
12/29/2017John McgrathCFOSell32,000$20.00$640,000.00View SEC Filing  
12/29/2017John McgrathCFOSell32,000$20.00$640,000.0096,654View SEC Filing  
12/28/2017Isaac E CiechanoverCEOSell2,200$15.15$33,330.00743,675View SEC Filing  
12/13/2017Isaac E CiechanoverCEOSell4,400$14.65$64,460.00743,675View SEC Filing  
11/30/2017Isaac E CiechanoverCEOSell4,400$14.25$62,700.00View SEC Filing  
11/17/2017Gad SofferEVPSell7,000$15.00$105,000.00166,342View SEC Filing  
11/16/2017Carol Giltner GallagherDirectorSell1,184$14.20$16,812.80110,105View SEC Filing  
11/15/2017Christopher HaqqEVPSell1,604$13.36$21,429.44344,134View SEC Filing  
11/14/2017Isaac E CiechanoverCEOSell4,400$13.47$59,268.00737,767View SEC Filing  
10/27/2017Isaac E CiechanoverCEOSell4,400$13.59$59,796.00737,767View SEC Filing  
10/16/2017Christopher HaqqEVPSell6,000$14.35$86,100.00View SEC Filing  
10/12/2017Isaac E CiechanoverCEOSell4,400$15.02$66,088.00View SEC Filing  
10/11/2017Isaac E CiechanoverCEOSell2,200$15.25$33,550.00737,767View SEC Filing  
9/20/2017Isaac E CiechanoverCEOSell4,400$15.54$68,376.00737,767View SEC Filing  
9/15/2017Christopher HaqqEVPSell6,000$15.30$91,800.00349,305View SEC Filing  
9/7/2017Isaac E CiechanoverCEOSell4,400$15.02$66,088.00737,767View SEC Filing  
8/23/2017Isaac E CiechanoverCEOSell4,400$13.54$59,576.00737,767View SEC Filing  
8/16/2017Carol Giltner GallagherDirectorSell1,184$14.30$16,931.20108,922View SEC Filing  
8/16/2017John McgrathCFOSell4,200$14.31$60,102.00125,157View SEC Filing  
8/16/2017Mitchall G. ClarkEVPSell3,021$14.33$43,290.93View SEC Filing  
8/15/2017Christopher HaqqEVPSell7,604$14.75$112,159.00362,909View SEC Filing  
8/11/2017Isaac E CiechanoverCEOSell4,400$14.67$64,548.00731,859View SEC Filing  
7/25/2017Isaac E CiechanoverCEOSell5,500$16.49$90,695.00731,859View SEC Filing  
7/24/2017Isaac E CiechanoverCEOSell2,800$16.94$47,432.00731,859View SEC Filing  
7/17/2017Christopher HaqqEVPSell6,000$14.92$89,520.00362,080View SEC Filing  
6/15/2017Christopher HaqqEVPSell6,000$12.65$75,900.00368,080View SEC Filing  
6/9/2017Carol Giltner GallagherDirectorSell1,000$13.15$13,150.00108,374View SEC Filing  
5/31/2017Isaac E CiechanoverCEOSell6,900$13.35$92,115.00731,859View SEC Filing  
5/30/2017Isaac E CiechanoverCEOSell3,450$13.44$46,368.00731,859View SEC Filing  
5/18/2017Isaac E CiechanoverCEOSell4,800$14.91$71,568.00731,859View SEC Filing  
5/16/2017Carol Giltner GallagherDirectorSell1,184$15.25$18,056.00103,741View SEC Filing  
5/16/2017Gad SofferEVPSell12,674$15.16$192,137.84259,527View SEC Filing  
5/16/2017John McgrathCFOSell4,000$15.11$60,440.00113,762View SEC Filing  
4/26/2017Isaac E CiechanoverCEOSell7,200$17.56$126,432.00725,951View SEC Filing  
4/25/2017Isaac E CiechanoverCEOSell3,600$17.33$62,388.00725,951View SEC Filing  
4/17/2017Christopher HaqqEVPSell6,000$17.28$103,680.00380,855View SEC Filing  
4/11/2017Isaac E CiechanoverCEOSell7,200$17.03$122,616.00725,951View SEC Filing  
3/28/2017Isaac E CiechanoverCEOSell16,000$20.06$320,960.00725,951View SEC Filing  
3/23/2017John McgrathCFOSell14,000$20.65$289,100.00119,327View SEC Filing  
3/17/2017Isaac E CiechanoverCEOSell30,800$19.38$596,904.00725,951View SEC Filing  
3/10/2017Gad SofferEVPSell2,500$20.00$50,000.00266,527View SEC Filing  
3/10/2017John McgrathCFOSell24,000$20.00$480,000.00126,827View SEC Filing  
2/21/2017John McgrathCFOSell9,000$15.14$136,260.00150,827View SEC Filing  
2/16/2017Carol Giltner GallagherDirectorSell1,183$16.10$19,046.30102,558View SEC Filing  
2/16/2017Isaac E CiechanoverCEOSell4,800$15.56$74,688.00725,951View SEC Filing  
2/16/2017Mitchall G. ClarkEVPSell3,059$15.96$48,821.64View SEC Filing  
2/15/2017Christopher HaqqEVPSell7,604$15.49$117,785.96400,459View SEC Filing  
2/10/2017Gad SofferEVPSell6,274$15.47$97,058.78269,938View SEC Filing  
2/9/2017Christopher HaqqEVPSell13,975$15.46$216,053.50399,630View SEC Filing  
2/3/2017Isaac E CiechanoverCEOSell4,800$13.66$65,568.00555,044View SEC Filing  
1/18/2017Isaac E CiechanoverCEOSell6,000$14.24$85,440.00555,044View SEC Filing  
1/17/2017Christopher HaqqEVPSell6,000$14.27$85,620.00364,105View SEC Filing  
1/6/2017Isaac E CiechanoverCEOSell8,400$16.89$141,876.00555,044View SEC Filing  
12/23/2016Isaac E CiechanoverCEOSell4,800$15.22$73,056.00555,044View SEC Filing  
12/15/2016Christopher HaqqInsiderSell6,000$15.40$92,400.00370,105View SEC Filing  
12/7/2016Isaac E CiechanoverCEOSell7,200$17.93$129,096.00555,044View SEC Filing  
11/23/2016Isaac E CiechanoverCEOSell12,000$18.34$220,080.00555,044View SEC Filing  
11/22/2016Isaac E CiechanoverCEOSell8,400$18.21$152,964.00555,044View SEC Filing  
11/16/2016Carol Giltner GallagherDirectorSell1,184$19.35$22,910.4099,377View SEC Filing  
11/16/2016Gad SofferCOOSell16,718$20.00$334,360.00225,667View SEC Filing  
11/16/2016Mitchall G ClarkInsiderSell2,995$19.53$58,492.3598,182View SEC Filing  
11/14/2016Gad SofferCOOSell9,582$20.55$196,910.10225,667View SEC Filing  
11/11/2016John McgrathCFOSell5,000$19.84$99,200.0091,823View SEC Filing  
10/27/2016Isaac E CiechanoverCEOSell4,800$13.81$66,288.00549,136View SEC Filing  
10/14/2016Isaac E CiechanoverCEOSell4,800$15.96$76,608.00549,136View SEC Filing  
10/12/2016John McgrathCFOSell5,000$17.47$87,350.0096,823View SEC Filing  
9/28/2016Isaac E CiechanoverCEOSell12,000$20.87$250,440.00406,578View SEC Filing  
9/16/2016Isaac E CiechanoverCEOSell7,200$19.36$139,392.00229,136View SEC Filing  
8/23/2016Isaac E CiechanoverCEOSell9,600$22.33$214,368.00229,136View SEC Filing  
8/16/2016Gad SofferCOOSell5,356$22.41$120,027.96146,460View SEC Filing  
8/15/2016Christopher HaqqInsiderSell1,346$22.32$30,042.72295,294View SEC Filing  
7/21/2016Isaac E CiechanoverCEOSell9,600$22.11$212,256.00223,228View SEC Filing  
7/8/2016Isaac E CiechanoverCEOSell9,600$22.88$219,648.00223,228View SEC Filing  
6/24/2016Isaac E CiechanoverCEOSell9,600$21.26$204,096.00223,228View SEC Filing  
6/8/2016Isaac E CiechanoverCEOSell12,000$20.53$246,360.00223,228View SEC Filing  
6/7/2016Isaac E CiechanoverCEOSell7,200$20.36$146,592.00223,228View SEC Filing  
5/26/2016Isaac E CiechanoverCEOSell7,200$17.69$127,368.00223,228View SEC Filing  
5/18/2016Carol Giltner GallagherDirectorSell1,184$15.96$18,896.6495,829View SEC Filing  
5/17/2016Gad SofferCOOSell5,427$15.91$86,343.57138,125View SEC Filing  
5/16/2016John McgrathCFOSell5,395$15.77$85,079.1586,519View SEC Filing  
5/16/2016Mitchall G ClarkInsiderSell4,153$15.15$62,917.9587,912View SEC Filing  
4/26/2016Isaac E CiechanoverCEOSell1,300$20.12$26,156.00217,321View SEC Filing  
4/12/2016Isaac E CiechanoverCEOSell13,210$20.40$269,484.00217,321View SEC Filing  
4/1/2016Isaac E CiechanoverCEOSell1,190$20.03$23,835.70217,321View SEC Filing  
3/17/2016Eric DobmeierDirectorBuy3,000$13.86$41,580.005,500View SEC Filing  
2/17/2016Carol Giltner GallagherDirectorSell1,183$16.30$19,282.9094,280View SEC Filing  
2/17/2016Gad SofferCOOSell5,711$16.77$95,773.47128,510View SEC Filing  
1/14/2016Isaac E CiechanoverCEOSell2,400$20.20$48,480.0047,440View SEC Filing  
12/31/2015Isaac E CiechanoverCEOSell2,400$26.00$62,400.0047,440View SEC Filing  
12/16/2015Eric DobmeierDirectorBuy2,500$22.00$55,000.002,500View SEC Filing  
12/15/2015Isaac E CiechanoverCEOSell2,400$22.46$53,904.0047,440View SEC Filing  
12/4/2015Isaac E CiechanoverCEOSell4,000$37.45$149,800.0047,440View SEC Filing  
11/30/2015John McgrathCFOSell6,000$40.00$240,000.0036,356View SEC Filing  
11/24/2015Isaac E CiechanoverCEOSell4,800$35.03$168,144.0047,440View SEC Filing  
11/17/2015Carol Giltner GallagherDirectorSell1,184$31.10$36,822.4093,098View SEC Filing  
11/17/2015Gad SofferCOOSell7,586$31.22$236,834.9272,013View SEC Filing  
10/22/2015Isaac E CiechanoverCEOSell3,200$25.85$82,720.0041,532View SEC Filing  
10/7/2015Isaac E CiechanoverCEOSell4,000$33.08$132,320.0041,532View SEC Filing  
9/24/2015Isaac E CiechanoverCEOSell5,200$42.99$223,548.0041,532View SEC Filing  
9/11/2015Isaac E. CiechanoverCEOSell5,200$46.16$240,032.0041,532View SEC Filing  
8/31/2015Christopher HaqqinsiderSell5,000$41.99$209,950.00240,890View SEC Filing  
8/28/2015Isaac E CiechanoverCEOSell5,200$39.25$204,100.0041,532View SEC Filing  
8/24/2015Carol Giltner GallagherDirectorSell17,622$42.34$746,115.4891,916View SEC Filing  
8/19/2015Carol Giltner GallagherDirectorSell5,875$48.18$283,057.50View SEC Filing  
8/18/2015Carol Giltner GallagherDirectorSell5,764$49.38$284,626.32View SEC Filing  
8/18/2015Gad SofferCOOSell7,711$49.49$381,617.39View SEC Filing  
8/18/2015John McgrathCFOSell6,000$49.38$296,280.00View SEC Filing  
8/17/2015Gad SofferCOOSell8,778$50.00$438,900.00View SEC Filing  
8/17/2015Mitchall G ClarkInsiderSell7,829$46.19$361,621.51View SEC Filing  
7/17/2015Isaac E CiechanoverCEOSell5,200$60.71$315,692.00View SEC Filing  
7/15/2015Christopher HaqqInsiderSell2,500$62.94$157,350.00View SEC Filing  
7/1/2015Christopher HaqqInsiderSell2,500$51.68$129,200.00View SEC Filing  
7/1/2015Isaac E CiechanoverCEOSell5,200$50.42$262,184.00View SEC Filing  
6/18/2015Isaac E CiechanoverCEOSell5,200$54.72$284,544.00View SEC Filing  
6/15/2015Christopher HaqqInsiderSell7,500$46.42$348,150.00View SEC Filing  
6/15/2015John McgrathCFOSell10,000$50.00$500,000.00View SEC Filing  
6/5/2015Isaac E CiechanoverCEOSell6,400$42.91$274,624.00View SEC Filing  
6/1/2015Christopher HaqqInsiderSell2,500$41.47$103,675.00View SEC Filing  
5/29/2015John McgrathCFOSell10,000$40.00$400,000.00View SEC Filing  
5/22/2015Isaac E CiechanoverCEOSell4,000$37.56$150,240.00View SEC Filing  
4/23/2015Isaac E CiechanoverCEOSell5,200$61.36$319,072.00View SEC Filing  
3/10/2015Joel S MarcusDirectorBuy4,000$29.57$118,280.00View SEC Filing  
2/18/2015Carol Giltner GallagherDirectorBuy11,000$18.00$198,000.00View SEC Filing  
10/21/2014Domain Partners Viii, L.P.Major ShareholderBuy248,159$11.00$2,729,749.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Atara Biotherapeutics (NASDAQ ATRA) News Headlines

Source:
DateHeadline
Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018
finance.yahoo.com - February 21 at 5:09 PM
Insider Selling: Atara Biotherapeutics Inc (ATRA) Director Sells 1,183 Shares of StockInsider Selling: Atara Biotherapeutics Inc (ATRA) Director Sells 1,183 Shares of Stock
www.americanbankingnews.com - February 20 at 9:46 PM
Isaac E. Ciechanover Sells 20,000 Shares of Atara Biotherapeutics Inc (ATRA) StockIsaac E. Ciechanover Sells 20,000 Shares of Atara Biotherapeutics Inc (ATRA) Stock
www.americanbankingnews.com - February 20 at 9:12 PM
John Mcgrath Sells 13,000 Shares of Atara Biotherapeutics Inc (ATRA) StockJohn Mcgrath Sells 13,000 Shares of Atara Biotherapeutics Inc (ATRA) Stock
www.americanbankingnews.com - February 20 at 9:12 PM
BidaskClub Upgrades Atara Biotherapeutics (ATRA) to "Strong-Buy"BidaskClub Upgrades Atara Biotherapeutics (ATRA) to "Strong-Buy"
www.americanbankingnews.com - February 19 at 3:54 PM
Atara Biotherapeutics (ATRA) Downgraded by Citigroup to SellAtara Biotherapeutics (ATRA) Downgraded by Citigroup to Sell
www.americanbankingnews.com - February 15 at 9:40 PM
Atara Biotherapeutics (ATRA) Stock Rating Upgraded by Zacks Investment ResearchAtara Biotherapeutics (ATRA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 15 at 5:40 PM
Atara Biotherapeutics Inc (ATRA) to Post Q1 2018 Earnings of ($0.89) Per Share, William Blair ForecastsAtara Biotherapeutics Inc (ATRA) to Post Q1 2018 Earnings of ($0.89) Per Share, William Blair Forecasts
www.americanbankingnews.com - February 15 at 10:10 AM
Atria had a strong year – strategy brought good resultAtria had a strong year – strategy brought good result
finance.yahoo.com - February 15 at 8:12 AM
Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 20,000 SharesAtara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 20,000 Shares
www.americanbankingnews.com - February 14 at 9:29 PM
Atara Biotherapeutics Inc (ATRA) Expected to Post Earnings of -$1.15 Per ShareAtara Biotherapeutics Inc (ATRA) Expected to Post Earnings of -$1.15 Per Share
www.americanbankingnews.com - February 14 at 5:16 PM
Atara Biotherapeutics Inc (ATRA) Forecasted to Post FY2022 Earnings of ($1.74) Per ShareAtara Biotherapeutics Inc (ATRA) Forecasted to Post FY2022 Earnings of ($1.74) Per Share
www.americanbankingnews.com - February 14 at 4:12 PM
Head-To-Head Contrast: Zymeworks (ZYME) vs. Atara Biotherapeutics (ATRA)Head-To-Head Contrast: Zymeworks (ZYME) vs. Atara Biotherapeutics (ATRA)
www.americanbankingnews.com - February 13 at 7:14 PM
Heather D. Turner Sells 12,214 Shares of Atara Biotherapeutics Inc (ATRA) StockHeather D. Turner Sells 12,214 Shares of Atara Biotherapeutics Inc (ATRA) Stock
www.americanbankingnews.com - February 12 at 9:16 PM
Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 8,800 SharesAtara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 8,800 Shares
www.americanbankingnews.com - February 12 at 6:30 PM
Atara Biotherapeutics (ATRA) Downgraded by Zacks Investment ResearchAtara Biotherapeutics (ATRA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 6 at 5:42 PM
Atara Biotherapeutics Inc (ATRA) Given Average Recommendation of "Buy" by AnalystsAtara Biotherapeutics Inc (ATRA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 6 at 1:56 PM
Atara Biotherapeutics (ATRA) Lowered to "Buy" at BidaskClubAtara Biotherapeutics (ATRA) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - February 3 at 2:44 PM
Understanding Atara Biotherapeutics’ Licensing and Collaboration AgreementsUnderstanding Atara Biotherapeutics’ Licensing and Collaboration Agreements
finance.yahoo.com - February 1 at 9:41 AM
Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 19,300 SharesAtara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 19,300 Shares
www.americanbankingnews.com - January 29 at 9:12 PM
Zacks: Analysts Anticipate Atara Biotherapeutics Inc (ATRA) to Post -$1.15 Earnings Per ShareZacks: Analysts Anticipate Atara Biotherapeutics Inc (ATRA) to Post -$1.15 Earnings Per Share
www.americanbankingnews.com - January 28 at 5:10 PM
Atara Biotherapeutics (ATRA) Coverage Initiated at CowenAtara Biotherapeutics (ATRA) Coverage Initiated at Cowen
www.americanbankingnews.com - January 27 at 10:30 AM
Isaac E. Ciechanover Sells 10,000 Shares of Atara Biotherapeutics Inc (ATRA) StockIsaac E. Ciechanover Sells 10,000 Shares of Atara Biotherapeutics Inc (ATRA) Stock
www.americanbankingnews.com - January 24 at 9:08 PM
Isaac E. Ciechanover Sells 48,500 Shares of Atara Biotherapeutics Inc (ATRA) StockIsaac E. Ciechanover Sells 48,500 Shares of Atara Biotherapeutics Inc (ATRA) Stock
www.americanbankingnews.com - January 24 at 9:08 PM
Proposals of Atria Plcs nomination board for the annual general meetingProposals of Atria Plc's nomination board for the annual general meeting
finance.yahoo.com - January 22 at 11:59 AM
Atara Biotherapeutics (ATRA) Receives "Positive" Rating from Canaccord GenuityAtara Biotherapeutics (ATRA) Receives "Positive" Rating from Canaccord Genuity
www.americanbankingnews.com - January 20 at 6:18 PM
Isaac E. Ciechanover Sells 600 Shares of Atara Biotherapeutics Inc (ATRA) StockIsaac E. Ciechanover Sells 600 Shares of Atara Biotherapeutics Inc (ATRA) Stock
www.americanbankingnews.com - January 18 at 8:30 PM
Atara Biotherapeutics: What The FDA Clearance For ATA-188 Phase 1 Study At US Sites Entails? - Seeking AlphaAtara Biotherapeutics: What The FDA Clearance For ATA-188 Phase 1 Study At US Sites Entails? - Seeking Alpha
seekingalpha.com - January 14 at 3:37 PM
Insider Selling: Atara Biotherapeutics Inc (ATRA) CFO Sells 37,000 Shares of StockInsider Selling: Atara Biotherapeutics Inc (ATRA) CFO Sells 37,000 Shares of Stock
www.americanbankingnews.com - January 12 at 9:28 PM
Atara Biotherapeutics Inc (ATRA) CEO Sells $613,893.00 in StockAtara Biotherapeutics Inc (ATRA) CEO Sells $613,893.00 in Stock
www.americanbankingnews.com - January 12 at 9:26 PM
Isaac E. Ciechanover Sells 8,600 Shares of Atara Biotherapeutics Inc (ATRA) StockIsaac E. Ciechanover Sells 8,600 Shares of Atara Biotherapeutics Inc (ATRA) Stock
www.americanbankingnews.com - January 12 at 9:26 PM
Atara Biotherapeutics Inc (ATRA) Given Average Rating of "Buy" by BrokeragesAtara Biotherapeutics Inc (ATRA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 12 at 1:38 PM
Atara Biotherapeutics Joins Elite Club Of Stocks With RS Ratings Over 90Atara Biotherapeutics Joins Elite Club Of Stocks With RS Ratings Over 90
finance.yahoo.com - January 12 at 11:22 AM
Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple SclerosisAtara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis
finance.yahoo.com - January 10 at 11:33 AM
Investors Buy High Volume of Put Options on Atara Biotherapeutics (ATRA)Investors Buy High Volume of Put Options on Atara Biotherapeutics (ATRA)
www.americanbankingnews.com - January 7 at 2:38 AM
Atara Biotherapeutics Sees Unusually Large Options Volume (ATRA)Atara Biotherapeutics Sees Unusually Large Options Volume (ATRA)
www.americanbankingnews.com - January 7 at 2:38 AM
Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAtara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 11:20 AM
Atara Biotherapeutics Inc (ATRA) CEO Sells $33,330.00 in StockAtara Biotherapeutics Inc (ATRA) CEO Sells $33,330.00 in Stock
www.americanbankingnews.com - January 3 at 12:58 AM
Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 22,200 SharesAtara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 22,200 Shares
www.americanbankingnews.com - January 3 at 12:28 AM
Atara Biotherapeutics Inc (ATRA) CFO Sells $640,000.00 in StockAtara Biotherapeutics Inc (ATRA) CFO Sells $640,000.00 in Stock
www.americanbankingnews.com - January 3 at 12:28 AM
Insider Selling: Atara Biotherapeutics Inc (ATRA) CFO Sells 32,000 Shares of StockInsider Selling: Atara Biotherapeutics Inc (ATRA) CFO Sells 32,000 Shares of Stock
www.americanbankingnews.com - January 3 at 12:28 AM
Atara Biotherapeutics Announces Proposed Offering of Common StockAtara Biotherapeutics Announces Proposed Offering of Common Stock
finance.yahoo.com - January 2 at 8:54 PM
Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
finance.yahoo.com - January 2 at 11:09 AM
ATARA Biotherapeutics (ATRA) Secures FDA Clearance to Begin Two Phase 3 Clinical Studies to Evaluate TabelecleucelATARA Biotherapeutics (ATRA) Secures FDA Clearance to Begin Two Phase 3 Clinical Studies to Evaluate Tabelecleucel
www.streetinsider.com - December 30 at 10:57 AM
Atara Biotherapeutics Inc. (ATRA) Is Surging On FDA ClearanceAtara Biotherapeutics Inc. (ATRA) Is Surging On FDA Clearance
www.nasdaq.com - December 30 at 10:57 AM
Atara Biotherapeutics (ATRA) Upgraded at ValuEngineAtara Biotherapeutics (ATRA) Upgraded at ValuEngine
www.americanbankingnews.com - December 29 at 9:26 PM
Atara Biotherapeutics (ATRA) "Buy" Rating Reaffirmed at Canaccord GenuityAtara Biotherapeutics' (ATRA) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - December 29 at 5:04 PM
Atara Biotherapeutics Wins FDA Clearance for Late-Stage TrialsAtara Biotherapeutics Wins FDA Clearance for Late-Stage Trials
finance.yahoo.com - December 29 at 3:36 PM
Atara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. ESTAtara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. EST
finance.yahoo.com - December 29 at 10:50 AM
Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
finance.yahoo.com - December 29 at 10:50 AM

SEC Filings

Atara Biotherapeutics (NASDAQ:ATRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Atara Biotherapeutics (NASDAQ:ATRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Atara Biotherapeutics (NASDAQ ATRA) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.